MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast ...

MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...

Genomic Health today announced the presentation of 11 studies with the Oncotype DX breast cancer test at the 14th St. Gallen Breast Cancer Conference in Vienna, Austria. Studies presented include ...

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score(R) ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...

Initial stage 0 DCIS assessment shifted to stage 1B invasive breast cancer after biopsy and MRI, necessitating surgery plus adjuvant radiation and chemotherapy. A 21-gene Oncotype DX score of 29 ...

It was this oncologist who had a very different recommendation: Try the Oncotype DX Breast Recurrence Score® test, a personalized genomic test designed to help determine her risk of distant recurrence ...

System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings. Telemedicine-supervised cancer therapy for patients with an aggressive lymphoma and metastatic ...

Chemotherapy decisions for young women with HR+ breast cancer and low recurrence scores reveal testing disparities that health systems must address. AJMC: Your analysis focused on chemotherapy use ...